We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ultrasis | LSE:ULT | London | Ordinary Share | GB0001494979 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.095 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
TIDMULT
RNS Number : 6149Z
Ultrasis PLC
12 December 2014
Ultrasis plc
("Ultrasis" or the "Company")
Announcement regarding share price movement
The Company notes the recent share price movement. The Board confirms that it remains in discussions with Paul Bell with regards the ongoing financing of the Company.
The Board is hopeful that Mr Bell may agree to lead a refinancing through a mixture of debt and equity. Any equity element is likely to be issued at a price of 0.05 pence per ordinary share, a substantial discount to the current share price. Current proposals being discussed would enable existing shareholders to participate in any equity offering alongside, and on the same terms, as Mr Bell.
Any refinancing would be subject to a number of a number of conditions, inter alia:
- the satisfactory conclusion of a limited due diligence exercise to be conducted by Mr Bell and/or other advisors appointed by Mr Bell for this purpose; and
- the approval of a waiver under Rule 9 of the Takeover Code as any significant equity investment would result in Mr Bell owning more than 30% of the voting rights in the Company
Discussions remain ongoing and there can be absolutely no certainty that an agreement can be reached.
For all enquiries relating to Ultrasis please contact:
Ultrasis plc Tel: +44 (0) 20 7535 2050 John Smith, Interim Executive Chairman finnCap Ltd Tel: +44 (0) 20 7220 0500 Geoff Nash/Simon Hicks
Notes to Editors:
Ultrasis is a healthcare company with core expertise in health, psychology, software development and programme management. We deliver a range of healthcare products to the consumer, the NHS, the corporate sector and other healthcare providers in the UK and Internationally. Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is still the world leader in this field.
This information is provided by RNS
The company news service from the London Stock Exchange
END
SPMUUUWRSVAUARA
1 Year Ultrasis Chart |
1 Month Ultrasis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
